peptides protocols FAQ

Yes, and the combination may accelerate recovery beyond BPC-157 alone. BPC-157 stimulates angiogenesis and collagen synthesis through VEGF upregulation, while Adamax's GH release enhances IGF-1 availability, which supports tissue remodeling and satellite cell activation. Inject BPC-157 near the injury site (or systemically if treating multiple areas) and Adamax in a separate subcutaneous region. Timing can be simultaneous because there's no receptor overlap. Run BPC-157 at 250–500mcg twice daily and Adamax at 150–200mcg once daily, fasted.

Adding Adamax to CJC-1295 creates a dual-pathway GH surge. GHRH receptor activation (CJC) plus ghrelin receptor activation (Adamax). Clinical data shows this combination produces higher peak GH levels than either peptide alone, making it effective for body recomposition. However, cycle length shortens: run 8–10 weeks maximum before taking a 4-week washout to restore receptor sensitivity. Dose both at full monotherapy levels (CJC-1295: 1–2mg weekly; Adamax: 150–200mcg daily). If you're already seeing strong results with CJC alone, adding Adamax may not be necessary. More isn't always better.

Limit stacks to three peptides maximum to avoid systemic overload and simplify timing logistics. A productive three-peptide protocol: Adamax (GH secretagogue) + MOTs-C (metabolic enhancer) + BPC-157 (repair peptide). Inject Adamax first (fasted), wait 45 minutes, inject MOTs-C, then inject BPC-157 at a separate site (timing flexible). This combination addresses three distinct endpoints. Hormonal anabolism, mitochondrial function, and tissue repair. Without receptor pathway redundancy. Running four or more peptides concurrently increases injection frequency to impractical levels and raises the risk of missing doses or contaminating reconstitution vials.

Pair Adamax with MOTs-C for complementary fat mobilization. Inject Adamax first (fasted state), wait 45 minutes, then administer MOTs-C. Adamax triggers GH-mediated lipolysis through hormone-sensitive lipase activation, while MOTs-C enhances mitochondrial fatty acid oxidation through AMPK signaling. Two separate steps in the fat-burning pathway. Standard dosing: 150–200mcg Adamax + 5–10mg MOTs-C, 5–6 days per week. Our FAT Loss Stack provides both peptides in research-grade purity with exact sequencing protocols.

Don't. Co-administration within 4–6 hours causes both peptides to compete for post-receptor signalling through mTOR and PI3K/Akt pathways. The result is reduced phosphorylation efficiency for both compounds. You get 60–75% of the response you'd see from staggered dosing. Separate by at least 8 hours. Follistatin-344 morning, GHRP evening is the standard protocol.

Triple stacks (follistatin-344 + GHRP + BPC-157) work well because BPC-157 operates through distinct pathways (VEGF upregulation, FAK phosphorylation for tissue repair) that don't interfere with myostatin or GH signalling. The key is keeping growth peptides (GHRPs, IGF analogs) separated from follistatin-344 by 8–12 hours while allowing repair peptides (BPC-157, TB-500) to run concurrently. Four-peptide stacks (adding IGF-1 LR3 or MK-677) are viable for advanced researchers but require precise timing to avoid receptor saturation.

Myostatin inhibition creates a permissive environment. It doesn't activate growth on its own. If you're running follistatin-344 solo without a growth-promoting peptide or adequate caloric surplus, you won't see meaningful hypertrophy. The compound removes a brake; you still need a gas pedal (GHRPs, IGF-1, or sustained caloric surplus with resistance stimulus). Follistatin-344 also requires consistent dosing. Every-other-day protocols work because the 36–48 hour myostatin block remains active. Dosing once weekly won't maintain the inhibition window.

Rotate injection sites across at least four areas (abdomen, thighs, deltoids, glutes) and ensure reconstitution uses bacteriostatic water rather than sterile water. The benzyl alcohol preservative in bacteriostatic water prevents bacterial growth but can cause mild irritation in sensitive individuals. If irritation persists, switch to sterile water and prepare smaller batches that are used within 3–5 days rather than the standard 28-day window. Injection depth also matters: subcutaneous injections should use a 29–31 gauge insulin syringe inserted at a 45-degree angle into pinched tissue. Injecting too shallow or too deep increases localized inflammation.

Increase carbohydrate intake on training days by 30–50g without reducing other macronutrients. The temporary caloric surplus on those days prevents the glycogen depletion that compromises strength and power output. Performance decline in a deficit typically signals inadequate carbohydrate availability rather than insufficient peptide dosing. Maintain the 500–700 calorie weekly deficit by reducing intake slightly on rest days. If performance doesn't recover within one week, implement a full diet break: eat at maintenance calories for 7–10 days with higher carbohydrate intake, then resume the deficit. The metabolic and hormonal reset from the break often restores training intensity without significantly delaying timeline to 10% body fat.

Reduce daily caloric intake by an additional 200–300 calories and implement a weekly refeed day at maintenance calories with higher carbohydrate intake (200–250g). Metabolic adaptation typically occurs after 6–8 weeks in deficit. Leptin drops, thyroid output decreases, and non-exercise activity thermogenesis (NEAT) declines by 200–400 calories per day. The refeed temporarily reverses these adaptations without significantly impacting weekly caloric deficit, allowing fat loss to resume. If the stall persists beyond two weeks post-refeed, consider adding Tesofensine research compound at 0.25–0.5mg daily. It inhibits reuptake of dopamine, norepinephrine, and serotonin, producing appetite suppression and thermogenic effects that counteract adaptive slowdown.